URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes.
|
27604308 |
2016 |
URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1
|
0.600 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we analyzed the ABCG2 gene in a hyperuricemia and gout cohort focusing on patients with pediatric-onset, i.e., before 18 years of age.
|
30894219 |
2019 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
This essentially includes our recent findings, as we serendipitously identified febuxostat, a well-used agent for hyperuricemia as a strong ABCG2 inhibitor, that possesses some promising potentials.
|
30890942 |
2019 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence demonstrates that congenital dysfunction of ABCG2 is an important genetic risk factor in gout and hyperuricemia; recent studies suggest the clinical significance of both common and rare variants of ABCG2.
|
31003562 |
2019 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We concluded that ABCG2 gene contributed to hyperuricemia but also gout, and that it was involved in the inflammation dysregulation via augmented IL-8 release in EC.
|
29453348 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism of ABCG2 Gene in Hyperuricemia Patients of Han And Uygur Ethnicity with Phlegm/Non-Phlegm Block in Xinjiang, China.
|
30197413 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
Hyperuricemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the possibility of treating gout and hyperuricemia by upregulating intestinal ABCG2 expression is examined.
|
29264928 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years.
|
29879316 |
2018 |
Hyperuricemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Plasma membrane expression of breast cancer resistance protein (BCRP), a uric acid efflux transporter, was decreased under hyperuricemia, though the total cellular expression of BCRP remained constant.
|
29317200 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Predictors of ULT misuse included the percentage of patients having gout (1-10%: OR=5.40, p=0.047) or receiving ULT (greater than 10-20%: OR=20.02, p=0.001)among patients seen in clinic, attendance of rheumatology conferences (OR=2.55, p=0.017), and having a close relative with hyperuricemia or gout (OR=2.45, p=0.026).
|
30520504 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Adenosine 5'-triphosphate-binding cassette subfamily G member 2 (ABCG2) is a urate transporter, and common dysfunctional variants of ABCG2, non-functional Q126X (rs72552713) and semi-functional Q141K (rs2231142), are risk factors for hyperuricemia and gout.
|
29342419 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study.
|
29453348 |
2018 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Common dysfunctional variants of ATP binding cassette subfamily G member 2 (Junior blood group) (ABCG2), a high-capacity urate transporter gene, that result in decreased urate excretion are major causes of hyperuricemia and gout.
|
28968913 |
2017 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Key findings include the reporting of 28 urate-associated loci, the discovery that ABCG2 plays a central role on extra-renal uric acid excretion, the identification of genes associated with development of gout in the context of hyperuricaemia, recognition that ABCG2 variants influence allopurinol response, and the impact of HLA-B*5801 testing in reducing the prevalence of allopurinol hypersensitivity in high-risk populations.
|
28566086 |
2017 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Not only does the 141K polymorphism in ABCG2 lead to hyperuricemia through renal overload and renal underexcretion, but emerging evidence indicates that it also increases the risk of acute gout in the presence of hyperuricemia, early onset of gout, tophi formation, and a poor response to allopurinol.
|
28461764 |
2017 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
It was first identified that rs2054576 in ABCG2 is associated with hyperuricemia.
|
28776340 |
2017 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
<i>Cichorium intybus</i> L. promotes intestinal uric acid excretion by modulating ABCG2 in experimental hyperuricemia.
|
28630638 |
2017 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Previous genome-wide association studies have found that the ABCG2 single nucleotide polymorphism (SNP) rs2231142 is an important genetic factor for increased uric acid (UA) levels, and the degree of association between rs2231142 and hyperuricemia is affected by both sex and ethnicity.
|
26792383 |
2017 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
ABCG2 and a novel gene, SLC17A4, contributed to the development of gout from hyperuricemia (OR = 1.56, P<sub>FDR</sub> = 3.68E-09; OR = 1.27, P<sub>FDR</sub> = 0.013, respectively).
|
28252667 |
2017 |
Hyperuricemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The ABCG2 141K variant and the FCU contribute strongly but independently to hyperuricaemia.
|
26835700 |
2016 |
Hyperuricemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Two important pathways determining hyperuricemia have been confirmed (renal and gut excretion of uric acid with glycolysis now firmly implicated).Major urate loci are SLC2A9 and ABCG2.
|
25889045 |
2015 |